2-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]-4-quinazolinamine

2-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]-4-quinazolinamine, also known as **CI-994**, is a compound that has shown promising activity as a **selective inhibitor of the enzyme Aurora kinase A**.

**Aurora kinase A** is a protein kinase that plays a crucial role in cell division, particularly in the process of mitosis. It is involved in regulating microtubule formation and chromosome segregation.

**Why CI-994 is important for research:**

* **Potential anti-cancer agent:** Aurora kinase A is often overexpressed in various cancer types, leading to uncontrolled cell growth and proliferation. CI-994's selective inhibition of this kinase has made it a promising candidate for the development of new cancer therapies.
* **Investigating Aurora kinase A's role in cell division:** CI-994 can be used as a tool to study the function of Aurora kinase A in normal and cancerous cells. By inhibiting its activity, researchers can investigate its role in various cellular processes and identify potential therapeutic targets.
* **Understanding the mechanism of action:** Studying CI-994's interactions with Aurora kinase A can provide valuable insights into the enzyme's structure and function, which can be used to design more effective and specific inhibitors.

**Current research on CI-994:**

* **Preclinical studies:** CI-994 has demonstrated anti-tumor activity in various preclinical models of cancer.
* **Clinical trials:** While CI-994 has not yet been approved for clinical use, there are ongoing clinical trials evaluating its safety and efficacy in patients with different cancer types.

**In summary,** CI-994 is a significant compound in cancer research due to its selective inhibition of Aurora kinase A and its potential as a novel anti-cancer therapeutic. Further research and clinical trials are ongoing to explore its full potential and its role in understanding the intricate mechanisms of cell division.